Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,196,750.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44GM077724-02
Agency Tracking Number:
GM077724
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
MOLECULAR DESIGN INTERNATIONAL, INC.
MOLECULAR DESIGN INTERNATIONAL, 111 South Highland Street, MEMPHIS, TN, 38111
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
075592597
Principal Investigator:
() -
Business Contact:
(901) 529-1919
purcell@moleculardesign.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Past studies from our laboratory have shown that topical pretreatment of diabetic rats with RA improves the healing of subsequently-induced abrasion wounds. The recently completed Phase I studies of this SBIR grant demonstrated that MDI 301 also improves healing of abrasion wounds in diabetic rats. The Phase II studies build on this. The workplan for the Phase II studies contains three specific aims: First, using the same model of strepto zotocin-induced diabetes in rats as used in the initial studies, we will determine the extent to which MDI 301 improves wound-healing in the skin. Second, using organ cultures of human skin obtained from diabetic subjects (skin from both at-risk and non-at -risk sites) we will determine the extent to which MDI 301 affects changes in physiology of human diabetic skin that contribute to successful wound healing. Finally, in aim three, we will continue the safety profiling of MDI 301 necessary for FDA approval. The overall goal of the proposed studies is to determine if topical pretreatment of skin with MDI 301 will, like RA itself, improve healing of subsequently-induced wounds but do so without provoking irritation. If it can be shown that MDI 301 is a s effective as RA but without the negative consequence seen with RA, it will provide a better agent for development as a chronic wound preventative.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government